AxoGen (NASDAQ:AXGN) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

AxoGen (NASDAQ:AXGN) announced its quarterly earnings data on Tuesday. The medical equipment provider reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by ($0.01), FiscalAI reports. The firm had revenue of $59.90 million during the quarter, compared to the consensus estimate of $59.90 million. AxoGen had a negative return on equity of 13.44% and a negative net margin of 6.97%.

Here are the key takeaways from AxoGen’s conference call:

• Strong 2025 financial performance — Q4 revenue $59.9M (+21.3% YoY) and FY revenue $225.2M (+20.2%), adjusted EBITDA up 41% to $27.9M, cash increased $6M, and the company generated positive cash flow while using $133.3M raised to retire its term loan and strengthen the balance sheet.
• Regulatory milestone — FDA BLA approval for Avance in December 2025 (first/only FDA‑approved biologic for peripheral nerve discontinuities with 12 years exclusivity) which management says enables payer engagement, prioritized clinical studies, and manufacturing scale efforts.
• Commercial momentum and runway — expanded sales force (breast to 21 reps with plan for ~30, extremities to 117 reps with plan for ~130), 679 active high‑potential accounts driving 61% of revenue growth, and continued surgeon education programs to support adoption.
• Near‑term margin and expense headwinds — Q4 net loss of $13.2M (versus prior year income) driven in part by $7.2M of one‑time stock‑based compensation tied to the BLA, materially higher R&D and S&M spend in Q4, and expected gross‑margin pressure in 2Q/H2 2026 as biologic mix increases before projected improvement in 2027.
• Reimbursement and new indications remain promising but early — commercial coverage rose to >65% (≈19.8M lives) and CMS added an outpatient payment classification improving economics, while prostate work (100+ procedures at 10 sites) may produce clinical signals in H2 2026 but is not expected to materially contribute revenue in 2026.

AxoGen Stock Performance

Shares of AXGN stock opened at $31.73 on Friday. The business has a 50-day simple moving average of $33.08 and a 200-day simple moving average of $25.07. The company has a quick ratio of 2.64, a current ratio of 5.11 and a debt-to-equity ratio of 0.51. The stock has a market cap of $1.65 billion, a PE ratio of -93.32 and a beta of 1.00. AxoGen has a 52-week low of $9.22 and a 52-week high of $36.00.

Insider Activity

In other AxoGen news, Director Paul Thomas sold 21,399 shares of the company’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $29.61, for a total transaction of $633,624.39. Following the completion of the transaction, the director directly owned 13,528 shares in the company, valued at approximately $400,564.08. This represents a 61.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Lindsey Marie Hartley sold 14,812 shares of the stock in a transaction on Monday, December 15th. The shares were sold at an average price of $29.86, for a total transaction of $442,286.32. Following the transaction, the chief financial officer directly owned 31,376 shares in the company, valued at approximately $936,887.36. The trade was a 32.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 301,680 shares of company stock valued at $9,174,052 in the last three months. Corporate insiders own 2.78% of the company’s stock.

Hedge Funds Weigh In On AxoGen

Hedge funds have recently made changes to their positions in the company. Aquatic Capital Management LLC grew its holdings in shares of AxoGen by 287.8% during the third quarter. Aquatic Capital Management LLC now owns 1,710 shares of the medical equipment provider’s stock worth $31,000 after buying an additional 1,269 shares in the last quarter. Arax Advisory Partners boosted its position in AxoGen by 362.4% during the fourth quarter. Arax Advisory Partners now owns 1,045 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 819 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in AxoGen during the 4th quarter valued at about $36,000. Kestra Advisory Services LLC acquired a new stake in AxoGen in the 4th quarter valued at about $39,000. Finally, Tower Research Capital LLC TRC raised its holdings in AxoGen by 189.9% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,079 shares of the medical equipment provider’s stock valued at $55,000 after acquiring an additional 3,327 shares during the last quarter. Institutional investors and hedge funds own 80.29% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on AXGN. Weiss Ratings restated a “sell (e+)” rating on shares of AxoGen in a report on Monday, December 29th. Jefferies Financial Group upped their price target on shares of AxoGen from $29.00 to $36.00 and gave the stock a “buy” rating in a research report on Thursday, December 4th. Canaccord Genuity Group lifted their price objective on shares of AxoGen from $27.00 to $37.00 and gave the company a “buy” rating in a report on Friday, December 5th. Mizuho initiated coverage on AxoGen in a report on Monday, December 1st. They set an “outperform” rating and a $40.00 target price for the company. Finally, Citizens Jmp increased their target price on AxoGen from $34.00 to $42.00 and gave the company a “market outperform” rating in a research report on Tuesday. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.67.

AxoGen Company Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.